Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain

L. Vécsei, Joanne Miller, Usha MacGarvey, M. Flint Beal

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Kynurenine is a direct precursor of kynurenic acid, the only known endogenous antagonist of excitatory amino acid receptors in the brain. Kynurenine administered intraperitoneally (150, 450, 900 mg/kg) 2 h before pentylenetetrazol injection dose-dependently increased the time to seizures, the time to death and the survivorship of mice. Kynurenine dose-dependently increased the time to seizures and the time to death in mice with NMDLA-induced seizures. Kynurenine, 900 mg/kg, was equally efficacious to diazepam, 2 mg/kg. Probenecid dose-dependently increased the time to seizures, the time to death and the survivorship of mice with pentylenetetrazol-induced seizures. Probenecid had no significant effects on NMDLA-induced seizures, although the time to death was prolonged in the NMDLA 500 mg/kg group. Probenecid potentiated the effects of kynurenine in these tests. Both probenecid and kynurenine significantly increased kynurenine and kynurenic acid concentrations in mouse cerebral cortex and striatum. These findings suggest that kynurenine (metabolized to kynurenic acid) has anticonvulsant effects, and probenecid potentiates these effects in mice.

Original languageEnglish
Pages (from-to)233-238
Number of pages6
JournalBrain Research Bulletin
Volume28
Issue number2
DOIs
Publication statusPublished - 1992

Fingerprint

Kynurenic Acid
Kynurenine
Probenecid
Pentylenetetrazole
Seizures
Brain
Glutamate Receptors
Diazepam
Cerebral Cortex
Anticonvulsants
Injections

Keywords

  • Kynurenic acid
  • Kynurenine
  • NMDLA
  • Pentylenetetrazol
  • Probenecid seizures

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. / Vécsei, L.; Miller, Joanne; MacGarvey, Usha; Flint Beal, M.

In: Brain Research Bulletin, Vol. 28, No. 2, 1992, p. 233-238.

Research output: Contribution to journalArticle

@article{9866aa152aaf4d9aa4376ab2491e9539,
title = "Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain",
abstract = "Kynurenine is a direct precursor of kynurenic acid, the only known endogenous antagonist of excitatory amino acid receptors in the brain. Kynurenine administered intraperitoneally (150, 450, 900 mg/kg) 2 h before pentylenetetrazol injection dose-dependently increased the time to seizures, the time to death and the survivorship of mice. Kynurenine dose-dependently increased the time to seizures and the time to death in mice with NMDLA-induced seizures. Kynurenine, 900 mg/kg, was equally efficacious to diazepam, 2 mg/kg. Probenecid dose-dependently increased the time to seizures, the time to death and the survivorship of mice with pentylenetetrazol-induced seizures. Probenecid had no significant effects on NMDLA-induced seizures, although the time to death was prolonged in the NMDLA 500 mg/kg group. Probenecid potentiated the effects of kynurenine in these tests. Both probenecid and kynurenine significantly increased kynurenine and kynurenic acid concentrations in mouse cerebral cortex and striatum. These findings suggest that kynurenine (metabolized to kynurenic acid) has anticonvulsant effects, and probenecid potentiates these effects in mice.",
keywords = "Kynurenic acid, Kynurenine, NMDLA, Pentylenetetrazol, Probenecid seizures",
author = "L. V{\'e}csei and Joanne Miller and Usha MacGarvey and {Flint Beal}, M.",
year = "1992",
doi = "10.1016/0361-9230(92)90184-Y",
language = "English",
volume = "28",
pages = "233--238",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain

AU - Vécsei, L.

AU - Miller, Joanne

AU - MacGarvey, Usha

AU - Flint Beal, M.

PY - 1992

Y1 - 1992

N2 - Kynurenine is a direct precursor of kynurenic acid, the only known endogenous antagonist of excitatory amino acid receptors in the brain. Kynurenine administered intraperitoneally (150, 450, 900 mg/kg) 2 h before pentylenetetrazol injection dose-dependently increased the time to seizures, the time to death and the survivorship of mice. Kynurenine dose-dependently increased the time to seizures and the time to death in mice with NMDLA-induced seizures. Kynurenine, 900 mg/kg, was equally efficacious to diazepam, 2 mg/kg. Probenecid dose-dependently increased the time to seizures, the time to death and the survivorship of mice with pentylenetetrazol-induced seizures. Probenecid had no significant effects on NMDLA-induced seizures, although the time to death was prolonged in the NMDLA 500 mg/kg group. Probenecid potentiated the effects of kynurenine in these tests. Both probenecid and kynurenine significantly increased kynurenine and kynurenic acid concentrations in mouse cerebral cortex and striatum. These findings suggest that kynurenine (metabolized to kynurenic acid) has anticonvulsant effects, and probenecid potentiates these effects in mice.

AB - Kynurenine is a direct precursor of kynurenic acid, the only known endogenous antagonist of excitatory amino acid receptors in the brain. Kynurenine administered intraperitoneally (150, 450, 900 mg/kg) 2 h before pentylenetetrazol injection dose-dependently increased the time to seizures, the time to death and the survivorship of mice. Kynurenine dose-dependently increased the time to seizures and the time to death in mice with NMDLA-induced seizures. Kynurenine, 900 mg/kg, was equally efficacious to diazepam, 2 mg/kg. Probenecid dose-dependently increased the time to seizures, the time to death and the survivorship of mice with pentylenetetrazol-induced seizures. Probenecid had no significant effects on NMDLA-induced seizures, although the time to death was prolonged in the NMDLA 500 mg/kg group. Probenecid potentiated the effects of kynurenine in these tests. Both probenecid and kynurenine significantly increased kynurenine and kynurenic acid concentrations in mouse cerebral cortex and striatum. These findings suggest that kynurenine (metabolized to kynurenic acid) has anticonvulsant effects, and probenecid potentiates these effects in mice.

KW - Kynurenic acid

KW - Kynurenine

KW - NMDLA

KW - Pentylenetetrazol

KW - Probenecid seizures

UR - http://www.scopus.com/inward/record.url?scp=0026580070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026580070&partnerID=8YFLogxK

U2 - 10.1016/0361-9230(92)90184-Y

DO - 10.1016/0361-9230(92)90184-Y

M3 - Article

C2 - 1596743

AN - SCOPUS:0026580070

VL - 28

SP - 233

EP - 238

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 2

ER -